LONG-TERM SURVIVAL EFFECTS OF PREOPERATIVE BREAST MRI IN PATIENTS WITH BREAST-CONSERVING SURGERY

Ahmet Serkan Ilgun1, Dauren Sarsenov2, Gul Alco3, Alper Ozturk4, Filiz Agacayak5, Filiz Elbuken6, Zeynep Erdogan7, Kezban Nur Pilanci8, Cetin Ordu9, Fatma Aktepe10, Gursel Soyibir11, and Vahit Ozmen12

1Department of Surgery, Demiroglu Bilim University, Istanbul, Turkey; 2Department of Surgery, Mater Dei Hospital, Msida, Malta; 3Department of Radiation Oncology, Gayrettepe Florence Nightingale Hospital, Istanbul, Turkey; 4Department of Surgery, Biruni University Medical School, Istanbul, Turkey; 5Department of Radiology, Istanbul Florence Nightingale Hospital, Istanbul, Turkey; 6Department of Radiology, Yeditepe University Medical School, Istanbul, Turkey; 7Physical Therapy and Rehabilitation Center, Biruni University Medical School, Istanbul, Turkey; 8Department of Medical Oncology, Memorial Bahcelievler Hospital, Istanbul, Turkey; 9Department of Medical Oncology, Gayrettepe Florence Nightingale Hospital, Istanbul, Turkey; 10Department of Pathology, Sisli Memorial Hospital, Istanbul, Turkey; 11Department of Surgery, Sisli Memorial Hospital, Istanbul, Turkey; 12Department of Surgery, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey

SUMMARY – The benefit of breast magnetic resonance imaging (MRI) in breast-conserving surgery (BCS) is unclear. Our study compared breast cancer patients with and without preoperative breast MRI and their long-term oncologic outcomes are reported. A total of 1378 BCS cases with early breast cancer between 1996 and 2017 were reviewed. Patients with carcinoma in situ or neoadjuvant treatment or having breast MRI after tumor excision were excluded. Of 1378 patients, 270 (19.5%) had preoperative MRI. There were no significant differences regarding T and N stage and molecular subtypes between the groups. Surgical margins were significantly wider in the breast MRI group. Five-year overall survival (OS) was 96.9% in the MRI group and 94.3% in the control group, and this difference was not significant (p=0.11). Five-year local-regional recurrence-free survival (LRFS) was not significantly different either (98.8% and 96.5%, respectively, p=0.41). When analyses were repeated only for patients with hormone receptor-negative or triple-negative breast cancer, there was still no significant difference in OS, LRFS, or disease-free survival. In conclusion, MRI does not seem necessary in all patients undergoing BCS. New prospective randomized controlled trials are needed to determine appropriate use of preoperative MRI and its effects on oncologic outcomes in early breast cancer patients.

Key words: Breast cancer; Breast MRI; Breast-conserving surgery; Overall survival; Local failure; Oncologic outcome

Introduction

Surgical treatment of breast cancer has evolved from radical mastectomy to breast-conserving surgery (BCS). Today, BCS with additional radiation therapy is the treatment of choice for early breast cancer1-3. By further...
developing oncoplastic surgical techniques, huge tumors can be treated without mastectomy with satisfying cosmetic results. However, with the more frequent use of BCS, multifocality and close/positive surgical margins have become an actual problem that requires re-excision or mastectomy. Patients with multifocality, positive lymphovascular invasion, positive axillary lymph nodes, or positive surgical margins are more likely to have residual tumors in re-excision or mastectomy specimens than others. Re-excision or mastectomy could be avoided in some patients with close margins with favorable factors such as unifocal tumors or node-negative diseases. Additional surgical procedures result in physical and psychological stress, extended hospital stays, and a higher likelihood of complications such as infections, hematomas, seromas, and fat necrosis.

In patients who undergo BCS, the traditional preoperative imaging modalities of the breast are mammography and ultrasound. However, it is known that other invisible tumor foci beyond 2 cm the index tumor are present in up to 16%-27% of patients. Magnetic resonance imaging (MRI) is more sensitive in detecting additional foci of disease than mammography and clinical breast examination. Furthermore, preoperative evaluation with MRI in patients with high breast density may help find additional tumor(s) and obtain precise tumor size and localization. Therefore, the use of preoperative contrast-enhanced MRI may better identify candidates for BCS and reduce re-excision and recurrence rates after surgery. On the other hand, MRI in the preoperative setting may cause increased mastectomy rates or unnecessary biopsies. It is also expensive and can cause delays in treatment.

Our study aimed to evaluate the effect of preoperative MRI on long-term survival in patients undergoing BCS in our breast department.

**Patients and Methods**

In this retrospective institutional review board-approved study, 1704 patients having undergone BCS for early-stage breast cancer in Istanbul Florence Nightingale Breast Health Center between 1996 and 2017 were identified. After excluding patients diagnosed with carcinoma in situ, those who underwent neoadjuvant treatment, had breast MRI after tumor excision, underwent mastectomy due to broad margin involvement after BCS, or were not followed up after surgery, 1378 patients remained and composed the entire study group. Two hundred and seventy patients had preoperative MRI and made up the MRI group. The patients underwent breast MRI for diagnostic purposes or determination of suitability for BCS before or after diagnostic core biopsy. The control group was made up of 1108 patients without preoperative breast MRI. All surgical treatments were performed according to oncologic principles at the time by a single surgeon. Re-excision was done if intraoperative or postoperative specimen examination showed positive or close (<2 mm) surgical margin(s). All patients were evaluated and discussed in the multidisciplinary tumor board regarding adjuvant treatment options. Locoregional recurrence was defined as any local failure in the ipsilateral breast or regional lymphatic fields. Disease-free survival (DFS) was defined as the period from diagnosis to the first disease recurrence at a local, regional or distant site, or the diagnosis of contralateral breast cancer.

Categorical variables of patients and tumor characteristics were compared using Pearson’s χ2-test or Mann-Whitney U test, as appropriate. The log-rank test was used to compare differences between survival curves derived by the Kaplan-Meier method. The Cox proportional hazard regression was used to model clinical outcomes such as overall survival (OS), local recurrence-free survival (LRFS), and DFS after BCS. All p-values from two-sided tests and a p-value ≤0.05 were considered statistically significant. Statistical analyses were performed with SPSS version 20.0 software (SPSS Inc., Chicago, IL, USA).

**Results**

Of 1378 patients, 270 (19.5%) had preoperative MRI. The patient median age was 50 (range, 23-88) years, and patients with preoperative MRI were significantly younger than patients in the control group (44 (26-81) vs. 51 (23-88), respectively, p<0.001). Preoperative MRI use increased after 2010 and became significantly higher after 2015 (Table 1).

There were 62 (23.3%) patients with multifocal tumors in the MRI group. Breast MRI could identify multifocal disease with 79% sensitivity and 77% specificity. Also, MRI could predict axillary lymph node involvement with 37.5% sensitivity and 88% specificity.

There were 48 (3.5%) patients who underwent re-excision after lumpectomy. Out of 48 patients, 45 (4.2%) patients were in the non-MRI group, whereas only three (1.1%) patients were in the MRI group (p=0.017).
### Table 1. Patient and tumor characteristics

|                              | Control group, n (%) | Study group, n (%) | p-value |
|------------------------------|----------------------|-------------------|---------|
| **Years**                    |                      |                   |         |
| 1996-2000                    | 23 (2.1)             | 0                 | <0.001* |
| 2000-2004                    | 96 (8.7)             | 4 (1.5)           |         |
| 2005-2009                    | 271 (24.5)           | 11 (4.1)          |         |
| 2010-2014                    | 526 (47.5)           | 136 (50.4)        |         |
| 2015-2017                    | 192 (17.3)           | 120 (44.1)        |         |
| **Age (yrs)**                | 51 (23-88)           | 44.5 (26-81)      | <0.001* |
| Age group (yrs)              |                      |                   | <0.001* |
| 20-29                        | 20 (1.8)             | 4 (1.5)           |         |
| 30-39                        | 126 (11.4)           | 67 (24.8)         |         |
| 40-49                        | 335 (30.2)           | 117 (43.3)        |         |
| 50-59                        | 288 (26.0)           | 46 (17.0)         |         |
| 60-69                        | 216 (19.5)           | 30 (11.1)         |         |
| 70-79                        | 100 (9)              | 5 (1.9)           |         |
| 80-89                        | 23 (2.1)             | 1 (0.4)           |         |
| **T stage**                  |                      |                   | 0.94*   |
| T1                           | 638 (57.6)           | 154 (57)          |         |
| T2                           | 449 (40.5)           | 110 (40.7)        |         |
| T3                           | 21 (1.9)             | 6 (2.2)           |         |
| **N stage**                  |                      |                   | 0.81*   |
| N0                           | 711 (64.2)           | 169 (62.6)        |         |
| N1                           | 238 (21.5)           | 64 (23.7)         |         |
| N2                           | 94 (8.5)             | 20 (7.4)          |         |
| N3                           | 65 (5.9)             | 17 (6.3)          |         |
| **Margin width (mm)**        | 10 (0-40)            | 6 (0-20)          | <0.001* |
| **Re-excision**              |                      |                   | 0.017*  |
| No                           | 1034 (95.8)          | 262 (98.9)        |         |
| Yes                          | 45 (4.2)             | 3 (1.1)           |         |
| **Tumor histopathology**     |                      |                   | 0.44*   |
| Invasive ductal              | 866 (80)             | 217 (80)          |         |
| Invasive lobular             | 77 (7)               | 14 (5)            |         |
| Other                        | 139 (13)             | 39 (15)           |         |
| **Unifocal/multifocal disease** |                  |                   | <0.001* |
| Unifocal                     | 946 (87.7)           | 204 (76.7)        |         |
| Multifocal                   | 145 (13.3)           | 62 (23.3)         |         |
| **Molecular subtype**        |                      |                   | 0.44*   |
| Lum A                        | 430 (40.0)           | 96 (35.8)         |         |
| Lum B                        | 467 (43.5)           | 123 (45.9)        |         |
| Her2 +                       | 60 (5.6)             | 13 (4.9)          |         |
| TNBC                         | 117 (10.9)           | 36 (13.4)         |         |

*χ²-test; *Mann-Whitney U test; TNBC = triple-negative breast cancer
Table 2. Survival: univariate analysis

|                              | n     | OS     | p-value | LRFS   | p-value | DFS    | p-value |
|------------------------------|-------|--------|---------|--------|---------|--------|---------|
| Preoperative breast MRI      |       |        |         |        |         |        |         |
| No                           | 1108  | 94.3%  | 0.11*   | 96.5%  | 0.41*   | 92.8%  | 0.09    |
| Yes                          | 270   | 96.9%  |         | 98.8%  |         | 98%    |         |
| Age (yrs)                    |       |        |         |        |         |        |         |
| <40                          | 218   | 95%    | 0.30*   | 94.5%  | 0.09*   | 92.6%  | 0.52    |
| ≥40                          | 1160  | 94%    |         | 97.1%  |         | 93.8%  |         |
| T stage                      |       |        |         |        |         |        |         |
| T1                           | 792   | 97%    |         | 97.3%  | 0.006*  | 95%    | 0.015*  |
| T2                           | 559   | 90%    |         | 96%    |         | 91.7%  |         |
| T3                           | 27    | 95.5%  |         | 94.1%  |         | 84.5%  |         |
| LN involvement               |       |        |         |        |         |        |         |
| no                           | 880   | 96.3%  |         | 97.1%  | 0.003*  | 94.4%  | 0.024*  |
| yes                          | 498   | 91.3%  |         | 96.1%  |         | 91.8%  |         |
| HG                           |       |        |         |        |         |        |         |
| I+II                         | 705   | 96.7%  |         | 98.7%  | 0.023*  | 97%    | 0.002*  |
| III                          | 620   | 92.7%  |         | 95%    |         | 90.5%  |         |
| LVI                          |       |        |         |        |         |        |         |
| No                           | 722   | 96.6%  |         | 97.7%  | 0.001*  | 95.7%  | 0.024*  |
| Yes                          | 614   | 92.5%  |         | 96.3%  |         | 91.8%  |         |
| ER                           |       |        |         |        |         |        |         |
| (-)                          | 266   | 87.5%  |         | 89.4%  | <0.001* | 86.4%  | <0.001* |
| (+)                          | 1096  | 96.4%  |         | 98.6%  |         | 95.2%  |         |
| PR                           |       |        |         |        |         |        |         |
| (-)                          | 404   | 90.1%  |         | 92.8%  | <0.001* | 90.5%  | <0.001* |
| (+)                          | 957   | 96.4%  |         | 98.5%  |         | 94.7%  |         |
| HER2                         |       |        |         |        | 0.42*   | 0.02*  | 0.28*   |
| (-)                          | 1078  | 94%    |         | 97.7%  |         | 94.5%  |         |
| (+)                          | 256   | 97.2%  |         | 93.5%  |         | 90.8%  |         |
| Molecular subtype            |       |        | <0.001* | <0.001*| 0.007*  |        |         |
| Lum A                        | 526   | 97.8%  |         | 99.2%  | <0.001* | 96.3%  |         |
| Lum B                        | 590   | 94.3%  |         | 97.8%  |         | 94%    |         |
| HER2 +                       | 73    | 84.2%  |         | 84%    |         | 84%    |         |
| TNBC                         | 153   | 85%    |         | 92.1%  |         | 89.3%  |         |
| Hormone receptor             |       |        |         |        | 0.001*  | <0.001*| 0.001*  |
| (-)                          | 226   | 89%    |         | 89.5%  |         | 87.7%  |         |
| (+)                          | 1116  | 96%    |         | 98.5%  |         | 95.1%  |         |

*Kaplan-Meier method; OS = overall survival at 5 years; LFRS: local recurrence-free survival at 5 years; DFS = disease-free survival at 5 years; MRI = magnetic resonance imaging; LN = lymph node; HG = histologic grade; LVI = lymphovascular invasion; ER = estrogen receptor; PR = progesterone receptor; TNBC = triple-negative breast cancer
There were no significant differences regarding T and N stage, histopathologic types, or molecular subtypes between the two groups. However, surgical margins were significantly wider in patients without preoperative breast MRI (Table 1).

Our median follow-up time was 56 (1-267) months. Among 1378 patients, 103 patients died during the follow-up period. Five-year OS rates were 96.9% in the MRI group and 94.3% in the control group, and this difference was not significant (p=0.11) (Table 2). When the analyses were repeated only for patients younger than 40, there was no survival difference between the two groups either (p=0.71).

In univariate analyses, T stage, lymph node involvement, histologic grade, lymphovascular invasion, estrogen receptor (ER) and progesterone receptor (PR) negativity significantly affected OS (Table 2).

In multivariate analyses, only hormone receptor negativity, lymph node involvement, and presence of lymphovascular invasion were significantly related to OS (Table 3).

Table 3. Overall survival: multivariate analysis

| Variable                        | HR   | 95% CI   | p-value |
|---------------------------------|------|----------|---------|
| Preoperative MRI (+ vs. -)      | 0.439| 0.17-1.09| 0.081   |
| Molecular subtype               |      |          |         |
| Lum A vs. TNBC                  | 0.306| 0.171-0.548| <0.001 |
| Lum B vs. TNBC                  | 0.408| 0.237-0.7 | 0.001   |
| Hormone receptor (- vs. +)      | 2.26 | 1.428-3.605| 0.001   |
| LVI (+ vs. -)                   | 1.83 | 1.108-3.032| 0.018   |
| LN involvement (+ vs. -)        | 1.57 | 1.001-2.489| 0.049   |

TNBC = triple-negative breast cancer; LVI = lymphovascular invasion; LN = lymph node; MRI = magnetic resonance imaging; HR = hazard ratio; CI = confidence interval

During the follow-up, 56 (4%) patients developed locoregional recurrence. Five-year LRFS rates were not significantly different between the two groups (96.5% and 98.8%, respectively, p=0.418) (Table 2). Only triple-negative and HER-2 (+) molecular subtypes were significantly related to lower LRFS rate (Table 4). In multivariate analyses, only hormone receptor negativity had significant adverse effects on LRFS (Table 4). Sixty-one patients developed systemic recurrence during follow-up, and DFS rate was 98% in the MRI group and 92.8% in the control group (p=0.099).

Table 4. Locoregional recurrence: multivariate analysis

| Variable                        | HR   | 95% CI   | p-value |
|---------------------------------|------|----------|---------|
| Preoperative MRI (+ vs. -)      | 0.569| 0.17-0.81| 0.35    |
| Molecular subtype               |      |          |         |
| TNBC vs. Lum A                  | 2.653| 0.17-0.799| 0.01    |
| TNBC vs. Lum B                  | 2.716| 0.18-0.844| 0.017   |
| TNBC vs. Her 2                  | 2.042| 0.84-4.78 | 0.113   |
| Her2+ vs. Lum A                 | 5.443| 2.37-12.47| <0.001  |
| Her2+ vs. Lum B                 | 5.027| 2.19-11.5 | <0.001  |

TNBC = triple-negative breast cancer; LN = lymph node; HG = histologic grade; MRI = magnetic resonance imaging; HR = hazard ratio; CI = confidence interval

Of 153 patients with triple-negative disease, 36 (23.5%) patients had preoperative MRI. Three of them died of systemic metastases, and one of them developed local recurrence. There was no significant difference regarding OS and LRFS rates between patients with triple-negative breast cancer in the two groups. When analyses were repeated only for patients with hormone receptor-negative disease, there was no significant between-group difference in OS, LRFS, or DFS (Table 5).

Table 5. Survival analysis in patients with hormone receptor negative disease

| Variable                        | n  | OS         | p-value | LRFS | p-value | DFS  | p-value |
|---------------------------------|----|------------|---------|------|---------|------|---------|
| Preoperative MRI (+)            | 49 | 90.3%      | 0.97    | 97.3%| 0.25    | 97.3%| 0.34    |
| Preoperative MRI (-)            | 177| 89.3%      |         | 88.5%|         | 86.2%|         |

OS = overall survival at 5 years; LRFS = local recurrence-free survival at 5 years; DFS = disease-free survival at 5 years; MRI = magnetic resonance imaging
Discussion

This study analyzed 270 patients with preoperative breast MRI out of 1378 patients diagnosed with clinically early-stage breast cancer and having undergone BCS. We were specifically interested in clinical outcomes such as OS, LRFS, and DFS between patients with and without preoperative MRI.

Clinical use of preoperative breast MRI gradually increased over time and significantly after 2010 in patients having undergone BCS (Table 1). This increase in MRI use might be related to change in the screening mammography age from 50 to 40 in 2010; this arrangement was made because half of the breast cancer patients in Turkey were younger than 50 years. The increase in free cancer screening programs, early detection, education centers, and mobile screening systems increased the early diagnosis of breast cancer in young women with dense breasts. Thus, it contributed to the more frequent use of breast MRI. Furthermore, technological improvements and easy access to MRI may have played a part. Breast MRI better visualizes the affected and contralateral breast in the preoperative setting and improves local control by detecting additional cancer.

Multiple studies have demonstrated that breast MRI detects foci of cancer not seen with other imaging modalities in 10% to nearly 30% of cases. In their study, Liberman et al. found that MRI imaging identified additional ipsilateral cancer sites in 27% of women, and the yield was highest in women with a family history of breast cancer or infiltrating lobular histology of index cancer. In another study evaluating the impact of preoperative MRI on BCS by Pengel et al., incomplete excision rate was not significant between the MRI and non-MRI groups even though the MRI group had lower rates (13.8% vs. 19.4%). In the same study, when stratified according to tumor type rather than lobular histology, incompletely excised infiltrating ductal carcinoma was significantly associated with absence of breast MRI. In a randomized control trial (COMICE), Turnbull et al. showed that reoperation rates in patients with preoperative MRI were not lower than in patients without MRI. In our study, the MRI group margin width was significantly lower than in the control group (6 mm vs. 10 mm). This could be owing to development of breast cancer treatment with a decreased adequate surgical margin width and the recent ‘no ink on tumor’ approach, and the fact that relatively newly diagnosed patients more frequently had MRI. Our overall re-excision rate was 3.5%. This relatively low rate could result from delicate intraoperative specimen evaluation by a very experienced breast pathologist. The re-excision rate in our study was significantly lower in the MRI group. It may have been due to better preoperative assessment resulting in reduced rates of incomplete excision.

Another critical issue in the clinical use of preoperative breast MRI is its possible benefits in oncologic outcomes. However, controversies exist whether detecting additional cancers by breast MRI is beneficial for survival. The possible effects of preoperative MRI on breast cancer local control are doubtful since randomized trials of BCS and mastectomy have demonstrated nearly equivalent results. In their retrospective study, Fisher et al. demonstrated decreased locoregional recurrence in patients undergoing BCS with preoperative MRI in a 40-month follow-up. On the other hand, two other retrospective studies showed no local recurrence or overall survival improvements if preoperative breast MRI was performed. Vapiwala et al. did not find a survival advantage of preoperative MRI in patients undergoing BCS in their 13-year follow-up. Similarly, in a study by Sung et al., survival benefit or local failure difference was not determined in their 8-year follow-up. Both studies included not only patients with invasive cancer but also patients with noninvasive disease. In another retrospective study examining patients over age 65 who underwent BCS, no significant difference in breast cancer-specific survival and OS were found between those who had preoperative breast MRI and those who did not. To the best of our knowledge, no randomized prospective trial has been conducted on long-term oncologic effects of preoperative breast MRI. However, the Alliance A11104 Clinical Trial from the American College of Radiology Imaging Network (ACRIN) is still ongoing. This ongoing study included only triple-negative and HER-2(+) molecular subtypes due to relatively low recurrence rates in patients with luminal subtypes. In their study, Gervais et al. defined a high-risk subgroup consisting of 39 patients with triple-negative and 30 patients with HER-2 (+) tumors. They investigated ipsilateral breast tumor recurrence in high-risk patients with or without preoperative breast MRI. Although ipsilateral breast tumor recurrence was higher in patients without preoperative breast MRI, the difference was
not significant (11.8% vs. 3.3%; p=0.3)^24. In our study, patients with triple-negative and HER-2(+) subtypes were grouped as a hormone receptor-negative sub-group. OS, LRFS, or DFS rates were not significantly different between the MRI and non-MRI groups (Table 5).

In our study, which included only patients with invasive breast cancer, there was no significant difference in tumor stage, tumor histologic features, or molecular subtypes, even though patients in the MRI group were significantly younger. Moreover, preoperative MRI was not associated with a statistically significant improvement in long-term oncologic outcomes. Since most patients with preoperative MRI were treated after 2010, we repeated our analyses only for those patients; preoperative breast MRI was still not associated with significant improvements in OS, LRFS, or DFS in these patients.

In the light of our current findings, we believe that preoperative MRI is not necessary to improve oncologic outcomes in all patients undergoing BCS. Since our study had limitations such as retrospective design and lack of adjuvant chemotherapeutic agent usage data, there might still be a subgroup of patients who can benefit from preoperative breast MRI. New prospective randomized controlled trials are necessary to determine the appropriate use of preoperative MRI for BCS patients and its effects on LRFS and OS rates in early breast cancer patients.

References

1. Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002 Oct 17;347(16):1233–41. doi: 10.1056/NEJMoA021522. PMID: 12393820.

2. Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002 Oct 17;347(16):1227–32. doi: 10.1056/NEJMoA020989. PMID: 12393819.

3. Eric I, Petek Eric A, Koprivčić I, Babić M, Pačarić S, Tuzlali S, et al. Positive or close margins in breast conservation surgery: is re-excision always necessary? Eur J Surg Oncol. 2012 May;38(5):399–406. doi: 10.1016/j.ejso.2011.12.018. Epub 2012 Mar 21. PMID: 22440741.

4. Nayar A, Gallagher KK, McGuire KP. Definition and management of positive margins for invasive breast cancer. Surg Clin North Am. 2018 Aug;98(4):761–71. doi: 10.1016/j.suc.2018.03.008. Epub 2018 Apr 24. PMID: 29005772.

5. Holland R, Veling SH, Mravunac M, Hendriks JH. Histologic multifocality of T1/T1–2 breast carcinomas. Implications for clinical trials of breast-conserving surgery.10.1002/1097-0142(19850901)56:5<979::aid-cncr2820560502>3.0.co;2-n. PMID: 2990668.

6. Esserman L, Hylton N, Yassa L, Barclay J, Frankel S, Sickles E. Utility of magnetic resonance imaging in the management of breast cancer: evidence for improved preoperative staging. J Clin Oncol. 1999 Jan;17(3):110–9. doi: 10.1200/JCO.1999.17.1.110. PMID: 10458224.

7. Liberman L, Morris EA, Dershaw DD, Abramson AF, Tan LK. MR imaging of the ipsilateral breast in women with percutaneously proven breast cancer. AJR Am J Roentgenol. 2003 Apr;180(4):901–10. doi: 10.2214/ajr.180.4.1800901. PMID: 12646427.

8. Sardanelli F, Giuseppetti GM, Panizza P, Bazzocchi M, Fausco A, Simonetti G, Lattanzio V, Del Maschio A; Italian Trial Management of positive margins for invasive breast cancer. AJR Am J Roentgenol. 2003 Jan;180(1):26–34. doi: 10.2214/ajr.180.1.1800795. PMID: 12496527; PMCID: PMC1513973.

9. Pengel KE, Loo CE, Teertstra HJ, Muller SH, Wesseling J, Peterse JL, et al. The impact of preoperative MRI on breast-conserving surgery of invasive cancer: a comparative cohort study. Breast Cancer Res Treat. 2009 Jul;116(1):161–9.
Does preoperative breast MRI effect survival?

doi: 10.1007/s10549-008-0182-3. Epub 2008 Sep 21. PMID: 18807269

16. Turnbull L, Brown S, Harvey I, Olivier C, Drew P, Napp V, et al. Comparative effectiveness of MRI in breast cancer (COMICE) trial: a randomised controlled trial. Lancet. 2010 Feb 13;375(9714):563-71. doi: 10.1016/S0140-6736(09)6070-5. PMID: 20159292

17. Poggi MM, Danforth DN, Sciuto LC, Smith SL, Steinberg SM, Liewehr DJ, et al. Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy: the National Cancer Institute Randomized Trial. Cancer. 2003 Aug 15;98(4):697-702. doi: 10.1002/cncr.11580. PMID: 12910512.

18. van Dongen JA, Voogd AC, Fentiman IS, Legrand C, Sylvestre RJ, Tong D, et al. Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. J Natl Cancer Inst. 2000 Jul 19;92(14):1143-50. doi: 10.1093/jnci/92.14.1143. PMID: 10904087.

19. Fischer U, Zachariae O, Baum F, von Heyden D, Funke M, Liersch T. The influence of preoperative MRI of the breasts on recurrence rate in patients with breast cancer. Eur Radiol. 2004 Oct;14(10):1725-31. doi: 10.1007/s00330-004-2351-z. Epub 2004 Jul 10. PMID: 15248080.

20. Vapiwala N, Hwang WT, Kushner CJ, Schnall MD, Freedman GM, Solin LJ. No impact of breast magnetic resonance imaging on 15-year outcomes in patients with ductal carcinoma in situ or early-stage invasive breast cancer managed with breast conservation therapy. Cancer. 2017 Apr 15;123(8):1324-32. doi: 10.1002/cncr.30479. Epub 2016 Dec 16. PMID: 27984658.

21. Sung JS, Li J, Da Costa G, Patil S, Van Zee KJ, Dershaw DD, et al. Preoperative breast MRI for early-stage breast cancer: effect on surgical and long-term outcomes. AJR Am J Roentgenol. 2014 Jun;202(6):1376-82. doi: 10.2214/AJR.13.11355. PMID: 24848838.

22. Onega T, Zhu W, Weiss JE, Goodrich M, Tosteson ANA, DeMartini W, et al. Preoperative breast MRI and mortality in older women with breast cancer. Breast Cancer Res Treat. 2018 Jul;170(1):149-57. doi: 10.1007/s10549-018-4732-z. Epub 2018 Mar 7. PMID: 29516372; PMCID: PMC5994182.

23. American College of Radiology Imaging Network (2013) Effect of preoperative breast MRI and surgical outcomes. https://www.acrinc.org/ports/0/proto cols/6694/0111 04_v04_13_summary.pdf.

24. Gervais MK, Maki E, Schiller DE, Crystal P, McCready DR. Preoperative MRI of the breast and ipsilateral breast tumor recurrence: long-term follow up. J Surg Oncol. 2017 Mar;115(3):231-7. doi: 10.1002/jso.24520. Epub 2017 Jan 20. PMID: 28105662.

Sažetak

DUGOROČNI UČINAK PRIJEOPERACIJSKE MAGNETSKE REZONANCIJE NA PREŽIVLJENJE U BOLESNICA S POŠTEDNOM OPERACIJOM RAKA DOJKE

A.S. Ilgun, D. Sarsenov, G. Ako, A. Ozturk, F. Agacayak, F. Elbunken, Z. Erdogan, K.N. Pilanci, C. Ordu, F. Aktepe, G. Soybir i V. Ozmen

Koristi od magnetske rezonancije (MR) kod operativnog zahvata kojim dojka ostaje očuvana u većoj ili manjoj mjeri (breast-conserving surgery, BCS) ostaju nejasne. U ovoj studiji uspoređene su bolesnice s rakom dojke u kojih je napravljena prijeoperacijska MR i one bez MR (kontrolna skupina) te se navode njihovi dugoročni onkološki ishodi. Pregledani su podatci za 1378 žena s ranim rakom dojke između 1996. i 2017. godine. Bolesnice s karcinomom in situ ili neoadjuvantnim liječenjem ili pak one kod kojih je učinjena MR nakon ekscizije tumora nisu uključene u istraživanje. Od 1378 bolesnica prijeoperacijska MR učinjena je u njih 270 (19,5%). Nije bilo značajnih razlika između dviju skupina s obzirom na T i N stadij te molekularne podtipove karcinoma. Kirurške granice bile su značajno šire u skupini s MR. Petogodišnje ukupno preživljenje bilo je 96,9% u skupini s MR i 94,3% u kontrolnoj skupini; ova razlika nije bila značajna (p=0,11). Petogodišnje preživljenje bez lokalnog-regionalnog recidiva (local-regional recurrence-free survival, LRFS) također se nije značajno razlikovalo između dviju skupina (98,8% odnosno 96,5%, p=0,41). Kad su analize ponovljene samo za bolesnice s rakom dojke negativnim na receptore ili trostruko negativnim rakom dojke nisu utvrđene nikakve značajne razlike u ukupnom preživljenju, LRFS ili preživljenju bez bolesti. Zaključno, izgleda da MR nije potrebno raditi u svih bolesnica u kojih se planira BCS. Nova prospektivna randomizirana kontrolirana istraživanja su potrebna kako bi se utvrdila odgovarajuća primjena prijeoperacijske MR te njezinu učincu na onkološke ishode u bolesnica s ranim rakom dojke.

Ključne riječi: Rak dojke; MR dojke; Poštedna operacija dojke; Ukupno preživljenje; Lokalni neuspjeh; Onkološki ishod